α受体阻滞剂结合电子生物反馈治疗Ⅲ型前列腺炎效果分析

摘要

目的:探讨α受体阻滞剂结合电子生物反馈治疗Ⅲ型前列腺炎的疗效.方法:经门诊确诊的Ⅲ型前列腺炎患者97例,随机分为对照组(48例)和实验组(49例).对照组仅接受α受体阻滞剂治疗,实验组接受α受体阻滞剂联合电子生物反馈治疗.两组均接受4周疗程治疗,并分别于治疗前、后进行美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)评分,同时参考治疗后前列腺按摩液(EPS)常规检查结果作为疗效评价指标.结果:对照组治愈2例(4.17%),显效4例(8.33%),有效13例(27.08%),无效29例(60.42%),总有效19例(39.58%);实验组治愈6例(12.24%),显效8例(16.33%),有效17例(34.69%),无效18例(36.73%),总有效31例(63.27%).两组总有效率比较,差异有统计学意义(P＜0.05).4周疗程后,实验组CPSI各项指标均较对照组明显改善,尤其排尿症状评分及总评分明显优于对照组,差异有统计学意义(P＜0.05或P＜0.01).对照组、实验组治疗后前列腺液常规正常者分别为12例(25.00%)、27例(55.10%),两组比较,差异有统计学意义(P＜0.05).本组无不良反应发生,无发生肛门外伤的并发症.结论:α受体阻滞剂结合电子生物反馈治疗是治疗Ⅲ型前列腺炎安全、效果良好的方法.%Objective: To evaluate the efficacy of α-blockers combined with electronic biofeedback therapy in the treatment of type Ⅲ prostatitis. Methods: The clinic diagnosed 97 cases of type Ⅲ patients with prostatitis were randomly divided into control group (48 cases) and experiment group (49 cases). They were both received 4 weeks therapy. The control group received only α-blocker therapy, the experiment group received α-blockers combined electronic biofeedback therapy. The U.S. National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score was used to assess two groups before and after treatment, respectively. Prostate massage fluid (EPS) routine examination results were also recorded after treatment as indicators of efficacy evaluation. Results: In the control group, 2 cases (4.17％) were cured, 4 cases (8.33％) were effective, 13 cases (27.08％) were improved and 29 cases (60.42％) were ineffective, the total effective rate in the control group was 39.58％. In the experiment group, 6 cases (12.24％) were cured. 8 cases (16.33％) were effective,17 cases (34.69％) were improved, and 18 cases (36.73％) were ineffective. the total effective rate in the experiment group was 63.27％. There was statistical difference between the two groups (P＜0.05). After 4 weeks of treatment, the experiment group CPSI indicators improved significantly than the control group, especially in unnary symptoms and total scores, with the significantly statistical difference (P＜0.05 or P＜0.01). EPS routine examinations after treatment in two groups were normal in 12 cases (25.00％) of the control group, 27 cases (55.10％) of the experiment group. There was a statistically difference (P＜0.05) hetween the two groups. There were no side effects and anal trauma occurred. Conclusion: The combination of α-blocker treatment and electronic bio-feedback therapy is safe. effective in the treatment of type Ⅲ prostatitis.